Senti Biosciences Holdings, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · South San Francisco, CA
SNTI chart
What traders are saying about $SNTI
Latest postsSenti Biosciences Holdings, Inc. news
- SNTI Q3'26 Earnings: revenue estimate is 0 USD
TradingView ·
- Which Penny Stock Looks Riskiest: Acumen Pharmaceuticals (NASDAQ:ABOS), Senti Biosciences (NASDAQ:SNTI), Theriva Biologics (NYSEAMERICAN:TOVX), Context Therapeutics (NASDAQ:CNTX) or Hain Celestial (NASDAQ:HAIN)?
kalkine.ca ·
- What Does Tiny Market Value Mean: Theriva Biologics (NYSEAMERICAN:TOVX), 22nd Century Group (NASDAQ:XXII), Acumen Pharmaceuticals (NASDAQ:ABOS), Hain Celestial (NASDAQ:HAIN) and Senti Biosciences (NASDAQ:SNTI)?
kalkine.ca ·
- Can These Penny Stock Gains Last: 22nd Century Group (NASDAQ:XXII), Hain Celestial (NASDAQ:HAIN), Senti Biosciences (NASDAQ:SNTI), Acumen Pharmaceuticals (NASDAQ:ABOS) or Context Therapeutics (NASDAQ:CNTX)?
kalkine.ca ·
- BC-Most Active Stocks
Yahoo Finance ·
- Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Technology Platform
Yahoo Finance ·
- Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
Yahoo Finance ·
- Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
Yahoo Finance ·
- Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
Yahoo Finance ·
- Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
Yahoo Finance ·
- Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
Yahoo Finance ·
- Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
Yahoo Finance ·
Senti Biosciences Holdings, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $22,000 | $0 | $2.0M | $3.3M |
| Net income | -$61.4M | -$52.8M | -$71.1M | -$58.2M |
| Diluted EPS | $-2.73 | $-12.03 | $-16.01 | $-2.23 |
| Total assets (year end) | $51.2M | $97.8M | $119.5M | $180.8M |
| Cash and equivalents (year end) | $16.4M | $48.3M | $35.9M | $57.6M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Senti Biosciences Holdings, Inc.
- Ticker
- SNTI (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- South San Francisco, CA
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1854270
- Former names
- Senti Biosciences, Inc., Senti Biosciences, Inc.\, Dynamics Special Purpose Corp.
Frequently asked questions
What exchange is Senti Biosciences Holdings, Inc. listed on?
Senti Biosciences Holdings, Inc. trades on the Nasdaq under the ticker symbol SNTI.
What industry is Senti Biosciences Holdings, Inc. in?
Senti Biosciences Holdings, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Senti Biosciences Holdings, Inc. headquartered?
Senti Biosciences Holdings, Inc.'s business address on file with the SEC is in South San Francisco, CA.
When does Senti Biosciences Holdings, Inc.'s fiscal year end?
Senti Biosciences Holdings, Inc.'s fiscal year ends on December 31.
How much revenue did Senti Biosciences Holdings, Inc. report?
Senti Biosciences Holdings, Inc. reported $22,000 in revenue for calendar year 2025, according to its SEC filings.